PDS Biotechnology (NASDAQ:PDSB) Announces Quarterly Earnings Results, Beats Estimates By $0.07 EPS

PDS Biotechnology (NASDAQ:PDSB) posted its quarterly earnings results on Wednesday. The company reported ($0.30) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.37) by $0.07, reports.

PDS Biotechnology Trading Down 1.1 %

Shares of PDSB opened at $3.49 on Friday. PDS Biotechnology has a 12 month low of $2.59 and a 12 month high of $10.27. The stock’s 50-day moving average is $3.74 and its two-hundred day moving average is $4.75. The company has a debt-to-equity ratio of 0.45, a quick ratio of 4.33 and a current ratio of 4.56.

Analyst Upgrades and Downgrades

PDSB has been the subject of a number of research analyst reports. Cantor Fitzgerald restated an “overweight” rating on shares of PDS Biotechnology in a report on Thursday, May 9th. StockNews.com lowered PDS Biotechnology from a “hold” rating to a “sell” rating in a research note on Saturday, March 16th. B. Riley reaffirmed a “buy” rating and issued a $11.00 price objective (down from $14.00) on shares of PDS Biotechnology in a research note on Thursday, March 28th. Finally, HC Wainwright reissued a “buy” rating and set a $21.00 target price on shares of PDS Biotechnology in a research report on Wednesday. One analyst has rated the stock with a sell rating and four have given a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $17.33.

Institutional Investors Weigh In On PDS Biotechnology

A number of large investors have recently modified their holdings of PDSB. Commonwealth Equity Services LLC boosted its holdings in PDS Biotechnology by 4.8% in the 3rd quarter. Commonwealth Equity Services LLC now owns 66,578 shares of the company’s stock worth $336,000 after acquiring an additional 3,025 shares during the period. Cary Street Partners Investment Advisory LLC lifted its position in shares of PDS Biotechnology by 187.7% during the third quarter. Cary Street Partners Investment Advisory LLC now owns 6,131 shares of the company’s stock worth $31,000 after purchasing an additional 4,000 shares in the last quarter. WINTON GROUP Ltd boosted its stake in shares of PDS Biotechnology by 24.8% in the third quarter. WINTON GROUP Ltd now owns 21,256 shares of the company’s stock valued at $107,000 after purchasing an additional 4,221 shares during the period. Inspirion Wealth Advisors LLC grew its holdings in PDS Biotechnology by 1.7% during the 4th quarter. Inspirion Wealth Advisors LLC now owns 336,594 shares of the company’s stock valued at $1,733,000 after purchasing an additional 5,720 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC purchased a new stake in PDS Biotechnology during the 3rd quarter worth $30,000. Institutional investors and hedge funds own 26.84% of the company’s stock.

About PDS Biotechnology

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.